Nicholas C Turner

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
    Somaia Elbauomy Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, Queen s Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, UK
    Breast Cancer Res 9:R23. 2007
  2. ncbi Basal-like breast cancer and the BRCA1 phenotype
    N C Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London, UK
    Oncogene 25:5846-53. 2006
  3. ncbi A therapeutic target for smoking-associated lung cancer
    Nicholas C Turner
    Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Sci Transl Med 2:62ps56. 2010
  4. ncbi FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 70:2085-94. 2010
  5. ncbi Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
    N Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 29:2013-23. 2010
  6. ncbi Fibroblast growth factor signalling: from development to cancer
    Nicholas Turner
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK, and Royal Marsden Hospital, London SW3 6JJ, UK
    Nat Rev Cancer 10:116-29. 2010
  7. ncbi Management of breast cancer--Part II
    Nicholas C Turner
    Department of Medical Oncology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG
    BMJ 337:a540. 2008
  8. ncbi Integrated functional, gene expression and genomic analysis for the identification of cancer targets
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 4:e5120. 2009
  9. ncbi FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo
    Rachel Sharpe
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 17:5275-86. 2011
  10. ncbi Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1
    Marieke Aarts
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research Breast Unit, UK
    Cancer Discov 2:524-39. 2012

Collaborators

Detail Information

Publications20

  1. ncbi FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis
    Somaia Elbauomy Elsheikh
    Department of Histopathology, School of Molecular Medical Sciences, Queen s Medical Centre, Nottingham University Hospitals Trust and University of Nottingham, Nottingham, UK
    Breast Cancer Res 9:R23. 2007
    ..Recent studies have demonstrated that specific FGFR1 amplification correlates with gene expression and that FGFR1 activity is required for the survival of a FGFR1 amplified breast cancer cell line...
  2. ncbi Basal-like breast cancer and the BRCA1 phenotype
    N C Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London, UK
    Oncogene 25:5846-53. 2006
    ..We review these phenotypes, the evidence for BRCA1 pathway dysfunction in sporadic basal-like cancers, and discuss the clinical significance of the basal-like phenotype for cancer genetics and treatment...
  3. ncbi A therapeutic target for smoking-associated lung cancer
    Nicholas C Turner
    Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Sci Transl Med 2:62ps56. 2010
    ..This genetic variation may represent the first relatively high-frequency therapeutic target of smoking-associated lung cancer...
  4. ncbi FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
    Nicholas Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Cancer Res 70:2085-94. 2010
    ..Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance...
  5. ncbi Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
    N Turner
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 29:2013-23. 2010
    ..0065). Our analysis demonstrates that TNBCs are heterogeneous tumours with amplifications of FGFR2 in a subgroup of tumours...
  6. ncbi Fibroblast growth factor signalling: from development to cancer
    Nicholas Turner
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK, and Royal Marsden Hospital, London SW3 6JJ, UK
    Nat Rev Cancer 10:116-29. 2010
    ....
  7. ncbi Management of breast cancer--Part II
    Nicholas C Turner
    Department of Medical Oncology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG
    BMJ 337:a540. 2008
  8. ncbi Integrated functional, gene expression and genomic analysis for the identification of cancer targets
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom
    PLoS ONE 4:e5120. 2009
    ..In conclusion, this strategy represents a novel and effective strategy for the identification of functionally important therapeutic targets in cancer...
  9. ncbi FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo
    Rachel Sharpe
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 17:5275-86. 2011
    ..Substantial evidence now links aberrant signaling by the fibroblast growth factor receptors (FGFR) to the development of multiple cancer types. Here, we examined the role of FGFR signaling in TN breast cancer...
  10. ncbi Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1
    Marieke Aarts
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research Breast Unit, UK
    Cancer Discov 2:524-39. 2012
    ..These features are characteristic of aggressive breast, and other, cancers for which WEE1 inhibitor combinations represent a promising targeted therapy...
  11. ncbi A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
    Christopher J Lord
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    DNA Repair (Amst) 7:2010-9. 2008
    ..Furthermore, the identification of these novel determinants may eventually guide the optimal use of PARP inhibitors in the clinic...
  12. ncbi Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer
    Elizabeth Iorns
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Cancer Cell 13:91-104. 2008
    ..The association of low levels of CDK10 with methylation of the CDK10 promoter suggests a mechanism by which CDK10 expression is reduced in tumors...
  13. ncbi A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
    Nicholas C Turner
    The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
    EMBO J 27:1368-77. 2008
    ..These results highlight the potential of synthetic lethal siRNA screens with chemical inhibitors to define new determinants of sensitivity and potential therapeutic targets...
  14. ncbi FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
    Jorge Sergio Reis-Filho
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 12:6652-62. 2006
    ..However, little is known about the putative therapeutic targets for these tumors. The aim of this study was to characterize CLCs at the molecular genetic level and identify putative therapeutic targets...
  15. ncbi Functional viability profiles of breast cancer
    Rachel Brough
    The Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom
    Cancer Discov 1:260-73. 2011
    ....
  16. ncbi Management of breast cancer--part I
    Nicholas C Turner
    Department of Medical Oncology, Royal Free Hospital NHS Foundation Trust, London NW3 2QG
    BMJ 337:a421. 2008
  17. ncbi A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer
    Monika Graeser
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Academic Department of Biochemistry, and Breast Unit, Royal Marsden Hospital, London, United Kingdom
    Clin Cancer Res 16:6159-68. 2010
    ....
  18. ncbi Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer
    Vikram K Jain
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 14:208. 2012
    ..We discuss the multiple therapeutic strategies in preclinical and clinical development and the current and future challenges to successfully targeting this pathway in cancer...
  19. ncbi Genetic heterogeneity and cancer drug resistance
    Nicholas C Turner
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Lancet Oncol 13:e178-85. 2012
    ..Here, we describe the potential role of clonal heterogeneity in resistance to targeted therapy, discuss genetic instability as one of its causes, and detail approaches to tackle intra-tumour heterogeneity in the clinic...
  20. ncbi BRCA1 dysfunction in sporadic basal-like breast cancer
    N C Turner
    Chester Beatty Laboratories, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Oncogene 26:2126-32. 2007
    ..0001). The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer...